Introduction
Aging is not just the passage of time but a complex biological process driven, among other things, by the accumulation of damaged, "stuck" cells called senescent cells. Although they stop dividing, they do not die. On the contrary — they secrete substances that cause inflammation and worsen the condition of the entire organism. Can we get rid of them? Yes. And that is exactly what senotherapy deals with.
Zombie cells: senescence in a nutshell
Senescent cells are like stuck CDs — they don’t fulfill their function but keep replaying the inflammatory signal. Over time, their accumulation leads to:
- chronic inflammatory states (inflammaging),
- increased cancer risk,
- weakened tissue regeneration,
- faster aging of organs (brain, heart, muscles).
Senotherapeutics: a precision weapon against aging
Senomorphics do not eliminate cells but modify their inflammatory activity (e.g., metformin, rapamycin). Senolytics are substances targeting the elimination of senescent cells. The best known:
- Dasatinib + quercetin (D+Q) — a combination used experimentally in human therapies,
- Fisetin — a natural flavonoid with senolytic action (used, for example, 2 g/day for 2 days per month),
- Navitoclax — a molecule studied in the context of heart and hematopoietic system aging.
What do studies show?
In animal models, senotherapeutics:
- improved insulin sensitivity and cognitive functions,
- restored muscle and lung tissue regeneration,
- extended average and maximum lifespan.
Initial clinical trials (Mayo Clinic, Unity Biotechnology) show the potential of therapy, for example, in idiopathic pulmonary fibrosis or osteoarthritis.
Is it safe?
This is an intensive intervention. Eliminating cells is not magnesium supplementation. Potential risks:
- tissue balance disruption,
- drug interactions,
- side effects with chronic use.
Therefore, pulsatile dosing is most commonly used (e.g., only 2 days per month) along with monitoring inflammatory and metabolic parameters.
How does senotherapy fit into the LLMe approach?
At LLMe, we understand longevity as the harmony of biological processes. Senolytics can:
- support autophagy, cleansing the body,
- reduce inflammation and support the action of resveratrol and spermidine,
- improve brain and mitochondrial regeneration (in combination with CDP-choline, Lion’s Mane, and PQQ).
It is one of the missing pieces in a complete anti-aging strategy.
Is senotherapy for everyone?
No. It is a tool for conscious adults with:
- chronic inflammation,
- past COVID infection,
- signs of muscular or cognitive aging,
- longevity optimization plan.
Recommended under specialist supervision or in a biohacking model with self-monitoring.
Summary
Senotherapy is the future of longevity medicine. Instead of masking the symptoms of aging, it reaches into its biological foundations. It eliminates what no longer serves — to make room for renewal.
This is not magic. This is science. But science from the future.
"We do not forcibly extend life. We free it from ballast."
Bibliography and sources
- Kirkland, J. L., Tchkonia, T., Zhu, Y., Niedernhofer, L. J., & Robbins, P. D. (2017). The Clinical Potential of Senolytic Drugs. Journal of the American Geriatrics Society, 65(10), 2297–2301.
- Zhu, Y., Tchkonia, T., Pirtskhalava, T., et al. (2015). The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell, 14(4), 644–658.
- Xu, M., Palmer, A. K., Ding, H., et al. (2018). Targeting senescent cells enhances adipogenesis and metabolic function in old age. eLife, 7, e32490.
- Justice, J. N., Nambiar, A. M., Tchkonia, T., et al. (2019). Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study. EBioMedicine, 40, 554–563.
- Hickson, L. J., Langhi Prata, L. G. P., Bobart, S. A., et al. (2019). Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of dasatinib plus quercetin in individuals with diabetic kidney disease. EBioMedicine, 47, 446–456.